A Phase Iiib, Open, Multi-center Study To Evaluate The Long-term Antibody Persistence At 6, 7, 8, 9 And 10 Years After The Administration Of One Dose Of The Meningococcal Conjugate Vaccine Menacwy-tt Versus One Dose Of Meningitec(Registered) Vaccine Or One Dose Of The Meningococcal Polysaccharide Vaccine Mencevax(Registered) Acwy, And To Evaluate The Safety And Immunogenicity Of A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Primary Vaccination Of 1-10 Year Old Subjects With Menacwy-tt, Meningitec(Registered) Or Mencevax(Registered) Acwy.

Trial Profile

A Phase Iiib, Open, Multi-center Study To Evaluate The Long-term Antibody Persistence At 6, 7, 8, 9 And 10 Years After The Administration Of One Dose Of The Meningococcal Conjugate Vaccine Menacwy-tt Versus One Dose Of Meningitec(Registered) Vaccine Or One Dose Of The Meningococcal Polysaccharide Vaccine Mencevax(Registered) Acwy, And To Evaluate The Safety And Immunogenicity Of A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Primary Vaccination Of 1-10 Year Old Subjects With Menacwy-tt, Meningitec(Registered) Or Mencevax(Registered) Acwy.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; Pfizer
  • Most Recent Events

    • 13 Sep 2017 Planned End Date changed from 1 Jun 2018 to 4 Jul 2018.
    • 13 Sep 2017 Planned primary completion date changed from 1 Feb 2018 to 20 Feb 2018.
    • 13 Sep 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top